Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution

Area of Science:

• Oncology
• Hematology
• Clinical Trials

Background:

• Brentuximab vedotin and PD-1 inhibitors (nivolumab, pembrolizumab) demonstrate high efficacy in relapsed/refractory Hodgkin lymphoma.
• These agents are being investigated for first- and second-line treatment of Hodgkin lymphoma.

Purpose of the Study:

• To evaluate the role and safety of brentuximab vedotin and PD-1 inhibitors in various lines of therapy for Hodgkin lymphoma.
• To assess the impact of these novel agents on treatment outcomes and toxicity profiles.

Main Methods:

• Review of preliminary data and clinical trial findings for brentuximab vedotin and PD-1 inhibitors.
• Analysis of response rates, relapse risk, and toxicity in different treatment settings (first-line, second-line, pretransplant salvage).

Main Results:

• Brentuximab vedotin alone is insufficient for newly diagnosed Hodgkin lymphoma in older adults but may reduce relapse risk when combined with standard chemotherapy in advanced stages.
• Second-line use of brentuximab vedotin, alone or with PD-1 inhibitors, shows high response rates as pretransplant salvage, though long-term outcomes need assessment.
• While generally well-tolerated as single agents, combinations have revealed toxicities, including pulmonary issues with bleomycin/brentuximab vedotin and infusion reactions.

Conclusions:

• Novel agents offer potential to improve Hodgkin lymphoma outcomes, aiming for eradication of recurrent disease.
• Careful consideration of efficacy and safety is crucial, especially regarding potential immune-mediated toxicities with first-line PD-1 inhibitor use.
• Combination regimens require further investigation to optimize benefit-risk profiles and manage unexpected toxicities.